ENHANZE® drug delivery technology: a novel approach to subcutaneous administration using recombinant human hyaluronidase PH20

ENHANZE® drug delivery technology: a novel approach to subcutaneous administration using recombinant human hyaluronidase PH20

ENHANZE® drug delivery technology is based on the proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20; Halozyme Therapeutics, Inc.) that facilitates the subcutaneous (SC) delivery of co‐administered therapeutics. rHuPH20 works by degrading the glycosaminoglycan hyaluronan (HA), which pl...

Full description

Bibliographic Details
Main Authors: Kenneth W. Locke, Daniel C. Maneval, Michael J. LaBarre
Format: Article
Language:English
Published: Taylor & Francis Group 2019-01-01
Series:Drug Delivery
Subjects:
recombinant human hyaluronidase ph20
rhuph20
hyaluronan
enhanze
subcutaneous
Online Access:http://dx.doi.org/10.1080/10717544.2018.1551442

Internet

http://dx.doi.org/10.1080/10717544.2018.1551442

Similar Items